Wells Fargo downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.

Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.

Downgrades

BMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market PerformJuly 26, 2016 10:44 AM BMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market PerformJuly 26, 2016 10:43 AM Stifel Downgrades Tokai Pharmaceuticals (TKAI) to HoldJuly 26, 2016 9:45 AM Janney Montgomery Scott Downgrades Tokai Pharmaceuticals (TKAI) to NeutralJuly 26, 2016 8:50 AM Tokai Pharma (TKAI) will resume trading at 7:30am ETJuly 26, 2016 7:20 AM Tokai Pharma (TKAI) to Cease ARMOR3-SV Clinical TrialJuly 26, 2016 7:05 AM Tokai Pharmaceuticals Announces Clinical UpdateJuly 26, 2016 7:00 AM Tokai Pharma (TKAI) trading halted with news pendingJuly 26, 2016 6:55 AM